Abstract:The increasing knowledge of molecular drivers of tumorigenesis has fueled targeted cancer therapies based on specific inhibitors. Beyond “classic” oncogene inhibitors, epigenetic therapy is an emerging field. Epigenetic alterations can occur at any time during cancer progression, altering the structure of the chromatin, the accessibility for transcription factors and thus the transcription of genes. They rely on post-translational histone modifications, particularly the acetylation of histone lysine residues, and are determined by the inverse action of histone acetyltransferases (HATs) and histone deacetylases (HDACs). Importantly, HDACs are often aberrantly overexpressed, predominantly leading to the transcriptional repression of tumor suppressor genes. Thus, histone deacetylase inhibitors (HDACis) are powerful drugs, with some already approved for certain hematological cancers. Albeit HDACis show activity in solid tumors as well, further refinement and the development of novel drugs are needed. This review describes the capability of HDACis to influence various pathways and, based on this knowledge, gives a comprehensive overview of various preclinical and clinical studies on solid tumors. A particular focus is placed on strategies for achieving higher efficacy by combination therapies, including phosphoinositide 3-kinase (PI3K)-EGFR inhibitors and hormone- or immunotherapy. This also includes new bifunctional inhibitors as well as novel approaches for HDAC degradation via PROteolysis-TArgeting Chimeras (PROTACs).

Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers.

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy

Histone Deacetylase Inhibitors as Anticancer Drugs

Current research status of histone deacetylase inhibitors in treatment of multiple myeloma

Histone deacetylases and cancer: causes and therapies

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy

New Development of HDAC Inhibitors As Anti-Cancer Agents

Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy

Anticancer activities of histone deacetylase inhibitors

Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers

The application of histone deacetylases inhibitors in glioblastoma

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

Targeting histone deacetylases for cancer therapy: Trends and challenges

Advances in the Application of Histone Deacetylase Inhibitors in Eye Disease

Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.

HDACi: molecular mechanisms and therapeutic implications in the innate immune system

HDACs and their inhibitors in immunology: teaching anticancer drugs new tricks

Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives